Published in
Oxford University Press, Journal of Antimicrobial Chemotherapy, 7(69), p. 1903-1910, 2014
DOI: 10.1093/jac/dku071
Links
Tools
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
Journal article published in 2014 by
L. Perez-Martinez,
P. Perez-Matute,
J. Aguilera-Lizarraga,
S. Rubio-Mediavilla,
J. Narro,
E. Recio,
L. Ochoa-Callejero 
,
J.-A. Oteo,
J.-R. Blanco
,
J.-A. Oteo,
J.-R. Blanco
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 